14-day Premium Trial Subscription Sign Up For FreeGet Free

Akebia Therapeutics Stock Forecast NASDAQ:AKBA

$2.00 (-1.96%)

Volume: 3M

Closed: Jan 21, 2022

Hollow Logo Score: -6.214

Akebia Therapeutics Stock Forecast

$2.00 (-1.96%)

Volume: 3M

Closed: Jan 21, 2022

Score Hollow Logo -6.214

Akebia Therapeutics Company Profile

245 First Street

Cambridge MA 02142



Industry: Biotechnology

Sector: Healthcare

Akebia Therapeutics


Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is AKB-6899, a small molecule HIF-PH inhibitor to treat oncology and ophthalmology. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE